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Nitric oxide- (NO-) dependent oxidative stress results in mitochondrial ultrastructural alterations and DNA damage in cases of
Alzheimer disease (AD). However, little is known about these pathways in human cancers, especially during the development as well
as the progression of primary brain tumors and metastatic colorectal cancer. One of the key features of tumors is the deficiency in
tissue energy that accompanies mitochondrial lesions and formation of the hypoxic smaller sized mitochondria with ultrastructural
abnormalities. We speculate that mitochondrial involvement may play a significant role in the etiopathogenesis of cancer. Recent
studies also demonstrate a potential link between AD and cancer, and anticancer drugs are being explored for the inhibition of
AD-like pathology in transgenic mice. Severity of the cancer growth, metastasis, and brain pathology in AD (in animal models
that mimic human AD) correlate with the degree of mitochondrial ultrastructural abnormalities. Recent advances in the cell-cycle
reentry of the terminally differentiated neuronal cells indicate that NO-dependent mitochondrial abnormal activities and mitotic
cell division are not the only important pathogenic factors in pathogenesis of cancer and AD, but open a new window for the
development of novel treatment strategies for these devastating diseases.

1. Introduction
Mitochondrial decay has been postulated to be a significant
feature underlying aging and age-related disease processes

[1]. Mitochondrial dysfunction and free radical-induced
damage play a significant role in the pathogenesis of tumors,
tumor-growth, metastasis, and cellular and tissue aging
[2]. Decline in mitochondrial function most likely leads to
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cellular energy deficits, especially during situations known to
require increased energy demand and in organs or tissues
where the energy needs and metabolic demand are particularly high, such as in the brain or fast-growing tumors.
These deficits can compromise vital adenosine triphosphate(ATP-) dependent cellular functions, such as detoxification, system repair, DNA replication, ATP-dependent protein degradation, and osmotic balance. As a result of this
increased energy demand coupled with hypoxia and oxidative stress, some tumors switch to glycolysis to meet energy
demands. Similarly, defective ATP production and increased
generation of reactive oxygen and nitrogen species (ROS and
RNS) may induce mitochondrial-dependent cell death as the
damaged mitochondria are unable to maintain the energy
demands of the cells [1].

2. Physiological Roles of NO and
NO Synthase (NOS)
NO, a free radical species, is a well-known physiological
signaling agent, and a pleiotropic regulator in various pathologies including tumor growth and AD [2, 3]. It is synthesized
by nitric oxide synthase (NOS) enzymes by transforming Larginine to L-citrulline. NOS enzymes comprise inducible
NOS (iNOS or NOS2), endothelial NOS (eNOS or NOS3),
and neuronal NOS (nNOS or NOS1) [2–6]. Various studies
have shown that each of the three isoforms may be implicated in either promotion or inhibition of human cancer
development. High amounts of iNOS expression, caused by
activated macrophages, may be cytostatic or cytotoxic for
tumor cells; in contrast, low activity may have an opposite
effect and promote tumor growth [2, 6]. In fact, nitric
oxide may play a crucial role in mitochondrial respiration
[4–6], since even low (nanomolar) concentrations of NO
were found to reversibly inhibit the mitochondrial respiratory chain enzyme cytochrome oxidase (complex IV) and
compete with molecular oxygen. Inhibition of cytochrome
oxidase by NO results in the reduction of the electrontransport chain, and favors the formation of the superoxide
radical anions (O2 − ). NO upon reaction with superoxide
radical anion forms peroxynitrite (ONOO− ), which is more
cytotoxic than NO itself [2, 3, 7]. Peroxynitrite has been
identified as a potent oxidant and potential mediator of
vascular tissue injury [3] and cell death [3, 7]. Several
laboratories have investigated the cellular consequences of
endogenously generated and exogenously applied NO [4–6].
Accumulating evidence demonstrates that endogenous NO
(using endothelial cells (EC)), basally produced or generated
in response to stimulation with bradykinin, reduces the rate
of oxygen consumption by the cells [8]. This finding suggests
that endogenous NO modulates oxygen consumption under
basal and stimulated conditions and leads to the formation
of reactive oxygen species, O2 ∙− [6]. Moreover, an extended
study by the Moncada’s group has found that prolonged
exposure to exogenous NO results in persistent inhibition
of mitochondrial respiration, which is localized mainly at
complex I [4–6]. This persistent inhibition seems to be
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the result of oxidative stress generated from mitochondrial
free-radical generation and involves S-nitrosylation of mitochondrial complex I. Indeed, inhibition of the respiratory
chain causes its reduction and the subsequent generation
of superoxide anions (vide supra). It is likely that these
anions are initially converted by superoxide dismutase to
hydrogen peroxide, which is known to be a transcription
factor of several defense genes. If this inhibition is prolonged,
it may result in the generation of peroxynitrite at the site of
superoxide anion production [6]. Thus, persistent inhibition
of cytochrome oxidase could elicit a two-stage response,
an early one in which the main consequence is the release
of small amounts of hydrogen peroxide (H2 O2 ), and a
later one that involves higher concentrations of H2 O2 and
formation of peroxynitrite. However, the mitochondrial DNA
overproliferation under these conditions is unknown [3].
Nevertheless, many of the biological effects attributed to NO
can be mediated by peroxynitrite [3]. Moreover, superoxide
and NO can be produced simultaneously in close proximity,
which leads to increased peroxynitrite formation [7]. Even
modest increases in both superoxide and NO formation
at a 10-fold greater rate increase peroxynitrite formation
by 100-fold. Under proinflammatory conditions, simultaneous production of superoxide and NO is rapidly activated
thereby increasing the production rates by 1,000-fold, which
consequently increase the formation of peroxynitrite by up
to 1,000,000-fold. The role of NO-induced mitochondrial
failure in the pathogenesis of tumors, particularly tumor
angiogenesis, now has been widely accepted. Recently, an
aging rat model of chronic brain hypoperfusion (CBH) that
mimics human mild cognitive impairment (MCI) was used to
examine the role of NOS isoforms on spatial memory function. In one of our studies, rats with CBH underwent bilateral
common carotid artery occlusion (2-vessel occlusion (2-VO)
were compared with nonoccluded sham controls (S-VO))
[9]. After the administration of neuronal and endothelial
(nNOS/eNOS) constitutive inhibitor nitro-L-arginine methyl
ester (L-NAME) only 2-VO rats worsened the ability of their
spatial memory [9]. Our findings indicate that vascular NO
derived from eNOS plays a critical role in spatial memory
function during CBH, possibly by keeping cerebral perfusion
optimal through its regulation of microvessel tone and
cerebral blood flow. This study could lead to the identification
of therapeutic targets for preventing MCI and treatment of
AD [9].
The role for NO-dependent process is quite clear in
AD pathogenesis and remodeling of cortical cholinergic
system through degradation of mature nerve growth factor
(NGF) in AD. It is also well established that the cortical
cholinergic system plays a crucial role in cognitive processing
and memory formation [10, 11]. Pharmacological evidence
of cholinergic atrophy and metastasis depends on matrix
metalloproteinases in both diseases. In an activity-dependent
manner NGF precursor forms proNGF, along with the
convertases and proteases necessary to form mature NGF
(mNGF) and to degrade the free, unbound mNGF by serine
protease involved the matrix metalloproteinase 9 (MMP9) [12]. However, the exact cellular mechanisms behind
tumor vascular growth and the relationship to NO oxidation
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products, such as nitrotyrosine products, lipid peroxidation,
as well as mitochondrial DNA (mtDNA) deletion remains
unknown [3].

3. The Role of Endothelin Signaling
During conditions favoring hypoxia, hypoxia-induced transcription factor (HIF-1) binds to the hypoxia response element (HRE) in the endothelin-1 (ET-1) promoter region
to induce ET-1 transcription [13]. In response to hypoxia,
oxidized low-density lipoprotein (LDL), cytokines, and ET1 levels are upregulated in EC [14]. The most extensively
studied member of the endothelin system or the so-called
endothelin axis and its expression is induced by various
cytokines and stimuli [14, 15], such as TNF stimulated ET1 secretion in cultured bovine airway smooth-muscle cells
(SMC) and human airway epithelial cells [16, 17]. The TNF
superfamily of cytokines are particularly important in cancer
progression and apoptosis.
The endothelin axis includes three endothelins (ET-1, ET2, and ET-3), which are widely expressed in various human
tissues including brain, skeleton muscle, testis, pancreas
and have similar structure [14] (along with two G-proteincoupled endothelin receptors (ET-RA and ET-RB), two proteinases) as endothelin converting enzymes (ECE-1 and ECE2) [18]. ET-1 and ET-2 bind to ET-RA more avidly than ET3, while all three endothelins have similar affinity for ETRB. When the primary physiological function of endothelins
was tested in arteries and veins, ET-1 and ET-2 induce
equal maximum contraction and potent responses, whereas
ET-3 induces lower maximum contractions and overall a
less potent response [19]. Likewise, ET-3 is a factor that
attenuates ET-1 signaling through ET-RA. ET-RA is found
predominantly in smooth and cardiac muscle cells, whereas
ET-RB is highly expressed in EC. ET-RA primarily mediates
vasoconstriction, contraction, and proliferation induced by
ET-1 [20] and is found predominantly in EC, where it
mediates endothelium-dependent vasodilation through NO
and prostacyclin. ET-RB is believed to have multiple effects,
including EC survival, NO production, and ET-1 clearance
[20]. Both ET-RA and ET-RB mediate antiapoptotic effects
in human SMC [21].
In many cases, increased levels of ET-1 and the receptors
(ET-RA, ET-RB) are detected in tumor tissues [14]. It has
been reported that ET-RA mediates ET-1 induced cancer cell
proliferation [22] and promotes epithelial-to-mesenchymal
transition [23]. ET-RB may mediate antiapoptosis effect
induced by ET-1 [24]. The loss of ET-3 expression due to
epigenetic inactivation has been reported in human breast
cancer by measuring mRNA levels [25]. This is consistent
with the speculation that ET-3 may attenuate ET-1 signaling
through ET-RA. It favors ET-1 signaling through ET-RA
when ET-3 is decreased in cancer cells. In order to understand
the detailed functions of endothelins in cancer, signaling
pathways in tumor cells initiated by the two different receptors need to be further explored. Diverse signaling pathways
from the two different receptors can be the reason why
endothelins and the receptors are regulated differently in
tumor tissues.
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Endothelin signaling is speculated to be involved in cell
differentiation, proliferation, migration, and angiogenesis in
tumors [25]. It has been demonstrated that ET-1 is overexpressed in various tumor tissues [22], including prostate
tumor and high grade prostatic intraepithelial neoplasia
[26], breast cancer [27], and lung tumor [28]. Expression
of mRNA of ET-1, ET-RA, and ET-RB was detected in
ovarian carcinoma cell lines HEY and OVCA 433 by RTPCR, and secreted ET-1 was detected in the culture media
by ELISA [22]. ET-1 and ET-RA are overexpressed in canine
ovary tumors [29], which is consistent with the function
of ET-RA signaling induced by ET-1 that is involved in
cell proliferation. However, transfection often results in a
supraphysiological level of expression of target genes, which
may induce some artifacts such as increased formation of
heterogeneous dimers between ETA and ETB receptors [30].
Although antagonists of endothelin receptors for the
treatment of cancer are not in clinical development, specific
peptide-based antagonists of ET-RA and ET-RB have been
used in in vitro and in vivo cancer studies. Cancer cell
proliferation was reported to be inhibited when ET-RA
was specifically blocked in colorectal cancer cell lines [31].
When orally active high affinity ET-RA antagonist ZD4054,
which has no detectable affinity for ET-RB, was applied in
vitro, it inhibited ET-1 induced proliferation of human preosteoblast cells [21], human ovarian carcinoma cell lines HEY
and OVCA 433 [22] and further demonstrated ET-RA was
involved in signaling in cancer cell proliferation.
ET-1 is a potent vasoconstrictor that induces contraction
at nanomolar concentrations in several vascular beds. Aliev
and coworkers and others have identified multiple inducers
of cell cycle reentry, ectopic cell cycle marker and ET-1
overexpression, as a hallmark of cancer, which is also involved
in AD [2, 3, 32]. The complex neurodegeneration mechanism
underlying AD, although incompletely understood, is characterized by an aberrant neuronal cell cycle reentry. While
cell cycle is not the focus of the present paper, the oncogenic
parallel between AD and cancer, especially in the context of
vascular content, is one the focus of this communication. The
pathological evidence of ectopic cell cycle marker and cell
cycle regulatory proteins expression in AD suggests that cell
cycle reentry is an earlier event, which occurs at prodromal
stages, that is, those stages which show formation of either
amyloid-beta (A𝛽) plaques or neurofibrillary tangles (NFTs)
as a hallmark for human AD and/or AD-like pathology in
transgenic mice [3, 32]. In this regard, Aliev and coworkers
have already demonstrated mitochondrial DNA deletion as
well as mitochondrial structural abnormalities in the vascular
walls of the human AD, yeast artificial chromosome (YAC),
and C67B6/SJL transgenic positive (Tg+) mice overexpressing amyloid amyloid-𝛽 precursor protein (A𝛽PP) [33]. We
expect similar findings in case of cancer as well, which most
likely could have an even more important role in cytotoxicity
and hypoxia adaptation by primary and metastatic cancerous
cells, as well as within the aging tissues including brain
itself. In this regard, recent advances in understanding the
pathogenesis of cell cycle reentry which relates the pathogenesis in AD as well as cancer deserves special attention.
Key in the AD pathogenesis is NO formation and release
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from vascular and immunologic cells and its conversion to
peroxynitrite, which nitrates tyrosine residues of enzymes,
and causes mitochondrial DNA damage [2, 3, 32]. Moreover,
Aliev and coworkers’ findings present a strong case for the
role of NOSs, ET-1, and their oxidation products such as
nitrotyrosine activity in the development of human colorectal
cancer metastasis to liver and in malignant brain cancers
[2].

4. GRK2 is Upstream in Endothelin
Signaling Cascades
NO production by EC seems to be regulated via Akt/PKB
signal transduction pathway, which activates eNOS. Akt
physically interacts with GRK2 and inhibits Akt activity
and its phosphorylation and thus production of NO [34].
In the aforementioned study, GRK2 expression increased
in sinusoidal endothelial cells from portal hypertensive rats
and knockdown of GRK2 restored Akt phosphorylation
and NO production, and normalized portal pressure. Thus,
an important mechanism underlying impaired activity of
eNOS in injured sinusoidal EC was found to be defective
phosphorylation of Akt caused by overexpression of GRK2
after injury (Figure 1).
Some of us and others [35–38] have also found a critical role of GRK2 in the endothelin signaling cascade and
many of the effects of ET-1 on cancer may be mediated by
GRK2 (Figure 2). In this regard, it is important to note the
importance of GRK2 on ET-1 receptors, downstream events,
and its relationship with cancer. The importance of the strong
immunologic relationship to most cancers is illustrated in
part by high expression of GRK2 in different cellular types of
the immune system. This emerges as an important regulator
of cell responses during inflammation, such as leukocyte
trafficking to the inflammatory foci, T-cell egression from
lymphoid organs, leukocyte activation, or proliferation [39].
GRK2 is known to phosphorylate chemokines and chemotactic receptors for CCR5, CCR2b, CXCR4, CXCR2, and
substance P, S1P or formyl-peptide, respectively [39].
Aberrant epithelial cell motility plays a key role in
cancer progression and metastasis. GRK2 expression levels
might alter migratory responses in pathological conditions
(Figures 1 and 2). A potential role for GRK2 in epithelial cell
migration was investigated by Penela and colleagues, where
GRK2 was found to promote actin cytoskeletal changes and
paxillin localization consistent with enhanced focal adhesion
turnover and higher cell motility [40]. These authors further
found that GRK2 promotes increased migration towards
fibronectin in different epithelial cell lines and in fibroblasts,
where these effects were independent of GRK2 kinase activity.
The contrary has been described in immune cells, where
increased GRK2 expression facilitates migration towards
fibronectin and GRK2 downregulation impairs migration
of the epithelial cells [40]. GRKs seem to be a new target
for therapeutic intervention. In addition to a currently
available ET receptor antagonist, overexpression of GRK2
attenuated ET-induced SMC proliferation and ETA receptor
desensitization mechanisms in vascular SMCs [35]. Guo
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and colleagues [41] showed TGF𝛽-induced GRK2 expression attenuates Angiotensin II-regulated vascular smooth
muscle cell proliferation and migration. GRK2 acts through
a negative feed-back loop mechanism to terminate TGFinduced SMAD signaling. Activation of the TGF𝛽 signaling
cascade in VSMCs results in increased GRK2 levels and
inhibits Angiotensin II-induced ERK phosphorylation, and
antagonizes Angiotensin II-induced VSMC proliferation and
migration at Mek-Erk interface [42]. Although ET-1 can
elicit prolonged physiologic responses, GRKs most likely
initiate ET-R desensitization. Moreover, endothelin A and
B receptors (ETA-R and ETB-R, resp.) can be regulated
indistinguishably by GRK-initiated desensitization. Furthermore, GRK2 and platelet-derived growth factor (PDGF) was
reported to attenuate SMC proliferation [43].
Finally, emerging evidence points a role of GRK2 as both
an extrinsic and intrinsic cell-cycle regulator. GRK2 expression is reported to have distinct impact on cell proliferation
and mitogenic signaling depending on both the cell type and
the mitogenic stimuli (Figures 1 and 2). It also has diverse
regulatory roles directly related to cancer. The complex
functional interaction networks during cell cycle progression
that are critical at particular stages of the cell cycle and in
cell cycle progression plays a critical role in driving timely
progression through G1/S and G2/M transitions in a kinasedependent and -independent manner through interaction
with CDK2/cyclinA and Pin1 [40]. In this regard, GRK2
levels are controlled normally by cell-cycle machinery and
in response to DNA damage and differentially contribute
either to cell cycle progression or cell arrest in a receptorindependent manner. When DNA is damaged, the pathways
can be disrupted and in this case GRK2 can promote
increased cell survival as a proarresting factor (see Figures
1 and 2). GRK2 protein levels are transiently downregulated
during the G2/M transition through CDK2-mediated phosphorylation of GRK2, and preventing GRK2 phosphorylation
impedes normal GRK2 downregulation and markedly delays
cell cycle progression [40]. Of importance is GRK2 protein
decay in G2, which is prevented in the presence of DNA damaging agents that trigger cell cycle arrest. Moreover, in cells
with higher steady-state levels of the kinases, increased stabilized GRK2 levels inversely correlate with the p53 response
and the induction of apoptosis [40]. Conversely, GRK2 is
reported to cooperate with known oncogenes in transformation assays [44] and GRK2 has regulatory roles, which
depend on extrinsic cues promoting cell division, as the
GRK2-mediated phosphorylation of Hedgehog/Smoothened
pathway triggers control of cell proliferation to promote
Smo activity and relieve the Patched-dependent inhibition of
cyclin B through Hedgehog ligand [45].
Certain signaling pathways instrumental in many cancers
cause the upregulation of GRK2 protein levels in malignant cell lines [46, 47]. It is known that altered GRK2
expression levels modulate chemokines-mediated induction
of MEK/ERK activity through both kinase-dependent and
-independent function [48] and its aberrant epithelial cell
motility that plays a key role in cancer progression and
metastasis (Figure 1). GRK2 protein levels have been differentially upregulated in tissue samples of patients with
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Figure 1: The hypothetical schematic drawing the potential role of GRK, MAPK, JNK, and p38 in the adaptive response during the
development and metastasis of the tumorigenesis.

granulose cell tumors, with differentiated thyroid carcinoma
[49, 50] or downregulated in a subgroup of prostate tumors
[51], which suggests that altered GRK2 expression in specific
tumor cells may affect migration in response to particular
stimuli and plays a critical role in basic cellular functions
such as cell proliferation, differentiation or migration during
development. Further, GRK2 inhibits TGF-mediated cell
growth arrest and apoptosis in human hepatocarcinoma cells
[46]. On the other hand, GRK2 attenuates serum- or PDGFinduced proliferation of thyroid cancer cell lines [49] and
smooth muscle cells [43], whereas its expression increases
MAPK signaling in response to EGF in HEK-293 cells [52]
and GRK2 kinase activity is required for IGF-1-triggered
proliferation and mitogenic signaling in osteoblasts [53]
(Figures 1 and 2).

5. The Role of NOSs and ET in Liver Colorectal
Metastatic Tumors
The absence of perivascular nerves in tumor vessels suggests
that endothelial derived vasoactive substance NO and ET1 may be the key factors in controlling tumor blood flow
during tumor growth and metastasis [2]. In our earlier study,
the ultrastructural distribution of different NOS isoforms
and ET-1 immunoreactivity in human colorectal metastatic
tumor liver was identified to know the role of NOSs and
ET-1 in the pathophysiology of colorectal metastatic tumors
by using preembedding peroxidase-anti-peroxidase (PAP)
and postembedding immunoelectron microscopic triple gold
labeling techniques [2].

Electron Microscopic PAP techniques determination of
the distribution of NOS1 immunolabeling features in control
(Figure 3(a)) and metastatic colorectal cancer liver tumor
tissues (Figures 3(b)–3(d) showed that NOS1 immunopositive EC were seen in control liver microvessels. In contrary
to these observations, tumor vessel endothelium showed
no staining for NOS1 antibody (Figure 3(b)). However,
presence of the NOS1 immunopositive white blood cells was
attached to vessel endothelium in tumor growth regions
often observed (Figure 3(c)). In addition, NOS1 immunopositive myofibroblast (smooth muscle cell) was also seen in
metastatic liver tumor tissues (Figure 3(d)).
Ultrastructural labeling of inducible NOS (NOS2) immunoreactivity in metastatic liver tumor tissues determined by
using electron microscopy and PAP immunocytochemical
techniques showed that almost all of tumor vessel EC was
positively stained with NOS2 (Figure 4(a)). Very often a high
intensity of NOS2 immunopositive precipitate accumulated
close to the luminal plasmalemma of the vascular EC in the
tumor growth region (Figure 4(b)), indicating the elevated
tissue levels of NO and ET-1 [2, 54]. The presence of NOS2
immunopositive hepatocytes and myofibroblast-like cells is
also seen throughout the tumor growth area (Figure 4(c)).
However, the lipid-contained areas of the cells were free from
PAP immunopositive reaction (Figures 4(c)-4(d)).
Ultrastructural features of endothelial specific NOS
(eNOS or NOS3) labeling in control (Figure 5(a)) and
metastatic liver tumors tissues (Figures 5(b)–5(d)) determined by using PAP method shows the presence a large
number of NOS3 immunopositive EC in control liver

6

Oxidative Medicine and Cellular Longevity

Role of GRK2 in AD

MDM2

7TM
GPC
𝛽
𝛽-AR
GRK2

P

𝛾

GRKs phosphorylate

P
P

Src + MAPK
P

G-protein

PI3K

Ras

GRK2
Ub
U
b
Ub
Ub
Ub
U
b
Ub

PLC
PKC

GRK2
accumulates

NF𝜅-B

AC

Raf

PKA

MEK

MEKK

ET-1
Insulin
resistance/
inhibition
Glut4

AKAP
cAMP
GRK2
BAD
Mitochondria
P
Ca

MKK
Anti-apoptotic

ROS/RNS

2+

eNOS

Myc

GRK2

ETBR

Endothelium
vascular
P
eNOS homeostasis
AKAP

NO

MAPK

PAK Raf MEKK MEK MAPK
GRK2
degradation/SI SAP/JNK p38 arrestins GPCRs
GRK2 ow turnover

JNKs
ERK
Gene regulation
Jun
Cell proliferation

Ca2+
PKC/PKB

S-nitrosothiols/NO
AD brain
CNS

GRK2

Ectopic production of
cyclins/Cdks
Attenuates
desensitization/
GPCR/GRK
internalization

Figure 2: The schematic drawing pattern of the GRK2 overexpression that most likely appeared to be as a compensatory to the hypoxia and
hypoperfusion induced oxidative stress that initiates the development and maturation of AD. Modified and reprinted with permission of CNS
Neurol Disord Drug Targets [92].

microvessels. NOS3 immunostaining was absent in EC in
tumor vessels (Figures 5(b)-5(c)). However, the presence
of NOS3 immunopositive hepatocytes in metastatic liver
tumors was seen. Lipid-enriched areas were free from NOS3
immunopositive precipitate (Figure 5(d)).
Our extended study by using postembedding triple
immunogold labeling techniques showed that the clusters
of NOS2 positive, but no NOS3 and ET-1 immunopositive containing gold particles were seen in tumor vessel
endothelium (Figure 6(a)). The expression of NOS1 containing positive gold particles was seen in the matrix of lipid
laden hepatocytes in tumor growth area (Figure 6(b)). Very
often the clusters of ET-1 but not NOS1 and NOS3 positive
gold particles in the cytoplasmic matrix of hepatocytes were
seen (Figure 6(c)). EC from metastatic liver microvessels
prepared as negative controls (through omission of the
primary antibody) showed only the presence of single gold
particles (Figure 6(d)). Our study highlights mitochondria as
a critical constituent responsible for cell viability, which can
be considered as a new research focus and of new diagnostic
criteria for the earlier detection of tumors as well as treatment
strategies at least in some tumors. However, further study
needs to be carried out in order to clarify the exact nature
of these relationships during the metastases and growth of
primary and/or metastatic tumors.

6. Mitochondrial Lesions and Oncogenic
Signaling Cascades
Aliev and coworkers’ ongoing studies suggest that the mitochondrial lesions are the hallmarks of the primary glioblastoma (Aliev et al., unpublished observation). Vessel endothelium from tumor tissues shows the damage of mitochondrial
cristae. The mitochondria-derived lysosomes appear to be a
permanent feature of the glioma-derived tumor cells. Lipid
laden tumor cells and surrounding cells often display varying
degrees of mitochondrial abnormalities (such as mitochondria with broken cristae, presence of edema in their matrix,
disruption of inner, and external mitochondrial membrane).
Moreover, giant mitochondria also appear to be permanent
features of tumor growth and metastases [2]. Comparatively
characteristics of marginal and central portion of tumor
tissues obtained from patients undergoing surgery with
diagnosis of the primary glioblastoma shows that distance
area of tumor tissue characterized heterogeneous distribution
of damage in the structure of the mitochondria. Central
regions of tumor tissues almost in all areas show astrocytes
with clusters of mitochondria-derived lysosomes (Aliev et
al., unpublished data). The same patterns of cellular and
subcellular damage were also seen in spinal cord tumor (Aliev
et al., unpublished data).

Oxidative Medicine and Cellular Longevity

7

(a)

(b)

(c)

(d)

Figure 3: Electron Microscopic Peroxidase-anti-Peroxidase immunocytochemical determination of the distribution of NOS1 immunolabeling features in control (a) and metastatic colorectal cancer liver tumor tissues (b)–(d). (a) NOS1 immunopositive EC (indicated by asterisk)
were seen in control liver microvessels. Vacuoles are indicated by single arrow X4 000. (b) Tumor vessel endothelium (indicated by asterisk)
showed no staining for NOS1 antibody. X20,000. (c) NOS1 immunopositive white blood cells (indicated by asterisk) were attached to vessel
endothelium in tumor growth regions. X6,000. (d) NOS1 immunopositive myofibroblast (smooth muscle cell) were seen in metastatic liver
tumor tissues. X10,000. Reprinted with permission of J Submicrosc Cytol Pathol [2].

For the detection of mitochondrial DNA over-proliferation and deletion in tumor cells in AD tissues, Aliev and
coworkers performed in situ hybridization [1, 32]. These
studies demonstrated that successful dysregulation of cell
cycle, and that early cell-cycle pathophysiology in AD may
recruit oncogenic signal transduction mechanisms, which
may be viewed as an abortive neoplastic transformation
prominent during tumorigenesis and AD. These results also
demonstrated that abnormal mitochondria and lipofuscin is a
feature of hippocampal damaged neurons in human AD and
aged AD transgenic (Tg+) mice that mimics human AD, and
suggest a direct relationship between vascular abnormalities,
BBB breakdown, neuronal loss, and amyloid depositions

[1, 32]. The giant and electron dense mitochondria were
reported to be a permanent feature of neuronal abnormality [1, 32]. In situ hybridization analysis with mouse and
human mtDNA probes showed a large amount of mtDNA
deletion in YAC-A𝛽PP mice hippocampus compared with
aged controls. The majority of these mtDNA deletions were
found in mitochondrial-derived lysosomes in regions closely
associated with lipofuscin, which suggests that proliferation,
deletion, and duplication of mtDNA occurs in mitochondria, many of which have been fused with lysosomes in
human AD [55–58], and transgenic mice as a model for
neurodegeneration [1, 32, 57, 58]. Moreover, biopsy samples
of AD patients were dominated by abnormal mitochondria
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Figure 4: Ultrastructural labeling of inducible NOS (NOS2) immunoreactivity in metastatic liver tumor tissues that determined by using Preembedding Peroxidase-anti-Peroxidase Electron Microscopy Immunocytochemical techniques. (a) Tumor vessel EC was positively stained
with NOS2. X8,000. (b) A high intensity of NOS2 immunopositive precipitate accumulated close to the luminal plasmalemma of the vascular
EC in the tumor growth region. X8,000. (c) NOS2 immunopositive hepatocytes (asterisk). Lipid-contained areas of the hepatocytes (double
arrow) were free from immunopositive reaction. X6,000. (d) NOS2 immunopositive myofibroblast-like cells (asterisk). X8,000. Reprinted
with permission of J Submicrosc Cytol Pathol [2].

as compared to control group. In one study, ultrastructural
localization of mtDNA by in situ hybridization with colloidal gold showed that deleted mtDNA is mainly found in
abnormal mitochondria [55]. The common features of the
mitochondrial abnormality were seen in the brain during
the tumorigenesis and in AD, indicating that most likely
mitochondrial DNA overproliferation/deletion appeared to
be key initiating factors for tumor growth/metastases [1, 32,
57, 58]. Therefore, investigating mitochondrial abnormality
may open new windows not only for the better understanding
of tumor pathogenesis but also for developing new treatment
strategies.
Of particular importance, the effect of mitochondrial
failure during tumor growth and metastases is dependent on
the following factors: oxygen deficient tissue, NOSs enzymes

activity, oxidative stress, cellular changes (hepatocytes, vascular, neuronal, and glial changes), and on the concomitant
mitochondrial lesions and decline in normal organ function
[1, 32, 57]. Upregulation of NOSs’ enzyme activity induces
formation of a large amount of reactive oxygen species
(ROS). This may be a key factor in mitochondrial damage
and energy failure occurring during carcinogenesis. Chronic
hypoxia, a predominant characteristic of tumors, initiates
the mitochondrial DNA overproliferation/deletion that then
induces formation of large quantities of unwanted free radicals with concomitant energy deficiency (Aliev unpublished
observations).
Some of the mitochondria mechanisms, which are incidentally heavily involved in the generation of ROS, result in
oxidative damage to the vascular endothelium, as well as to
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Figure 5: Ultrastructural features of endothelial specific NOS (eNOS or NOS3) labeling in control (a) and metastatic liver tumors tissues
(b–d) determined by using Peroxidase-anti-Peroxidase Immunocytochemistry. (a) A large number of NOS3 immunopositive EC (indicated
by arrows) were seen in control liver microvessels. X5,000. (b) NOS3 immunostaining was absent in EC (asterisk) in tumor vessels. X8,000.
(c) EC from tumor microvessels did not show the presence of any NOS3 immunopositive reaction. X10,000. (d) NOS3 immunopositive
hepatocytes (white asterisk) in metastatic liver tumors were seen. Lipid-enriched areas were free from NOS3 positive precipitate (arrows).
X8,000. Reprinted with permission of J Submicrosc Cytol Pathol [2].

other cellular constitutes in tumor tissues. Such changes also
accompany tumor pathology. Previous studies demonstrated
how age affects mitochondrial DNA mutations and overproliferation in liver and brain. Brain disorders that involve
chronic hypoperfusion may be responsible for concomitant
energy failure and the pathogenesis that underlies both disease processes, as hypoperfusion appears to induce oxidative
stress, which is largely from ROS as well as NO [3].
However, these underlying processes also play a role
not only in aging and age-associated diseases, but in tumor
growth and metastases. Over the time, these processes initiate
mitochondrial failure, a known factor in early AD pathogenesis [1, 32, 58]. In addition, NO can be produced for 80 years by
neurons in human brain without any toxicity. Paradoxically,
the production of the same molecule can become highly

damaging to the same neurons within a few minutes during
pathological challenges as occur after cerebral ischemia. The
reaction of NO with superoxide (O2 − ) to form the much more
powerful oxidant peroxynitrite (ONOO− ) is a key element
in resolving the contrasting roles of NO in physiology
and pathology (vide supra). Future studies comparing the
spectrum of mitochondrial damage and the relationship to
NO-dependent oxidative stress-induced damage during the
aging process [1, 32] and more importantly, during tumor
development and metastasis are warranted [2].
Various studies demonstrated the involvement of NO
in apoptosis and show that inhibition of mitochondrial
respiration by NO results in a relative degree of mitochondrial
hyperpolarization, an occurrence that requires the production of glycolytic ATP [6]. This observation indicates that
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Figure 6: The distribution of NOS1-3 and ET-1 immunopositive gold particles in metastatic tumor vessel endothelium and hepatocytes that
determined by using Post-embedding triple immunogold labeling techniques. (a) Clusters of NOS2 positive gold particles (20 nm, thick
arrows) but not NOS3 (5 nm, single thin arrow) and ET-1 (10 nm, double arrow) were seen in tumor vessel endothelium. X100,000. (b) The
expression of NOS1 (20 nm single arrow) was seen in the matrix of lipid laden hepatocytes in tumor growth area. NOS3 (10 nm) and ET1 (5 nm) positive gold particles indicated by double and thin single arrow. X100,000. (c) Clusters of ET-1 (20 nm, single arrows) but not
NOS1 (10 nm, double arrow) and NOS3 (5 nm, single thin arrow) positive gold particles in the cytoplasmic matrix of hepatocytes were seen.
X100,000. (d) EC from metastatic liver microvessels prepared as negative controls (through omission of the primary antibody) showed only
the presence of single gold particles (10 nm, double arrow). X100,000. Reprinted with permission of J Submicrosc Cytol Pathol [2].

the hyperpolarization may be a protective mechanism since
neurons, and perhaps, other cells which do not utilize the
glycolytic pathway and do not respond to NO by mitochondrial hyperpolarization, are more susceptible to NOinduced apoptosis than are glycolytically-active astrocytes
(for a review, see [6]). Persistent inhibition of respiration
by NO over a prolonged time eventually result in the
collapse of membrane potential, ATP depletion and, ultimately, cell death (for a review, see [6]). NO may reversibly
inhibit enzymes with transition metals or with free radical
intermediates in their catalytic cycle. NO in micromolar

concentrations reversibly inhibit catalase and cytochrome P450 (for a review see [7]), which may transiently increase the
leakage of superoxide from the electron transport chain. The
superoxide so formed could then react with NO to generate
peroxynitrite, which would cause irreversible injury to the
mitochondria (for a review, see [7]). It can also inhibit ribonucleotide reductase, the enzyme responsible for DNA synthesis
that contains a tyrosine radical. Large continuous fluxes of
NO are necessary to inhibit ribonucleotide reductase, which
would occur only under major inflammatory conditions or
in the neighborhood of an activated macrophage. Indeed,
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activated macrophages produce both NO and superoxides,
so the inactivation of mitochondria in tumor cells could well
have been mediated by peroxynitrite (for a review, see [7]).
An increase in the release of NO from the vascular
endothelium and other tumor tissue cells, including the
natural killer cells (NKH-lymphocytes), can promote antitumor growth activity. High NO concentrations are generally tumoricidal as it inhibits DNA synthesis [59, 60].
NO, through reactions from the products of mitochondrial
electron transport chain, produces ROS and RNS, which
in sufficiently high concentrations cause DNA damage and
apoptosis. Whereas DNA damage in cancer cells helps prevent cancer metastasis, it results in neuronal loss in AD.
Our report demonstrated that metastatic colorectal cancer to liver and malignant brain cancer are characterized
by overexpression of several NOS enzymes, which coexist
with mitochondrial ultrastructural alterations in tumor cells.
Moreover, the degree of tumor growth and metastasis is
linearly correlated with the overexpression of iNOS and
increased level of ET-1 immunoreactivity [2]. The role of ET1 as a mitogen in the pathogenesis of tumor growth and
metastasis has been studied extensively [2, 59, 60]. Aliev
and coworkers recorded expression of ET-1 immunoreactivity
not only in vascular endothelium, but also in tumor cells,
activated lymphocytes, SMC, and in liver hepatocytes [2, 54].
ET-1 has been reported as a mitogenic factor against a variety
of cell types including the human hepatocellular carcinoma
[61–64]. Studies by Nelson and coworkers [59, 60] found
that circulating plasma ET-1 was elevated in more than half
of men with advanced metastatic prostate cancer (PCA).
The elevation of plasma ET-1 levels has been reported in
hepatocellular carcinoma [64], but all patients in that study
also had cirrhosis, which is independently associated with
elevations in plasma ET-1 [65]. In many tissues, cellular overexpressions of ET-1 mRNA transcripts are in close proximity
with those possessing ET-1 receptors [66, 67]. It has been
suggested that the increased ET-1 immunoreactivity can be
used as a marker for tumor growth and metastases [2, 59,
60]. However, the exact cellular mechanisms behind tumor
vascular growth and the relation to NO oxidation products
identified as nitrotyrosine formation, lipid peroxidation, ET1 activity or mtDNA deletion remain to be unknown [2, 54].
Future studies comparing the spectrum of mitochondrial
damage and the relationship to NO-dependent oxidative
stress-induced damage during the aging process [1, 32, 57]
and more importantly, during development and metastasis
of tumor are in need of the hour. In addition, it has been
also suggested that NO influences cellular differentiation
through induction of gene expression [67]. This is interesting
because a constitutively expressed NOS2 has been described
in a colorectal adenocarcinoma cell line [68]. NO produced
by stimulated macrophages [69] or released by NO donor
drugs [70] inhibits tumor cell growth. Earlier, Aliev and
coworkers have highlighted rise of NOS2 immunoreactivity
as a hallmark in human metastatic colon cancer [2]. However
exact role of NOS2 activity on the mitochondrial lesions
and/or mitochondrial DNA overproliferation and/or deletion
in these conditions are unknown. The increased understanding of the relationship between the degree of mitochondrial
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lesions, NOS and nitrotyrosine protein overexpression, and
mitochondrial DNA overproliferation/deletion, could give
us a better understanding of tumor pathogenesis. This may
eventually lead to new and effective treatments strategies. For
example, if the degree of pathology can be correlated with the
quantity of the NOS enzymes, immunoreactivities expressed
and mtDNA overproliferation/deletion, then manipulating
the systems metabolically may be sought which can lead to
early death of the injured cancer cell mitochondria. Moreover,
mitochondria appear to be primary targets for apoptotic
cell death. Moreover, involvement of NO has already been
demonstrated in apoptosis and it has been shown that inhibition of mitochondrial respiration by NO results in a relative
degree of mitochondrial hyperpolarization, an occurrence
that requires the production of glycolytic ATP [6].
Cytokines increase NOS2 mRNA levels in macrophages,
hepatocytes, and vascular SMC’s in a dose- and timedependent manner [71]. An alternative explanation for the
increased NOS2 expression in vascular endothelium and all
NOS isoforms immunoreactivity in other cells in metastatic
liver tissue is that a large number of noncontractile types
of fibroblasts and/or myofibroblast-like cells are present in
tumor tissues. The marginal increase in NOS2 immunoreactivity in tumor vessel endothelium, along with the increased
expression of all three NOS isoforms in other cells in liver,
were associated with a significant overexpression of ET1 immunoreactivity in all tumor tissue cells. Our report
indicated that NOS2 and ET-1 expressions are linearly correlated with the degree and nature of tumor growth [2, 54].
It is interesting that the total number of NOSs (NOS 1–
3) immunopositive EC is nearly equal to the total number
of ET-1 immunopositive EC. We speculate that most likely
this positive feedback appears to be a compensatory action
of tumor invaded organs during the tumor growth and
metastases.

7. Oncogenic Parallelism between
Cancer and AD: Potential Common
Treatment Strategies
When cells receive growth stimuli, or mitotic drive, they
upregulate cyclin-dependent kinases (CDKs) and their cognate activating cyclins to orchestrate DNA replication,
cytoskeletal reorganization and cellular metabolism required
for proliferation (Table 1). Hormonal signals from luteinizing
hormone and other hormones can contribute to this mitotic
drive [72]. Mitotic drive and the orderly progression through
cell cycle, involve cyclins and CDKs which form complexes
that are able to phosphoregulate a wide variety of substrates
[73]. However, extrinsic mitotic pressures and proper cell
cycle progression can also involve resensitization. Association with AD and AD-related cytoskeletal pathology [74] may
be involved in aberrant neuronal sprouting response [75–
78]. Mitotic drive may arise from inflammatory processes,
oxidative stress and other excitatory stressors [79–81]. Strong
support exists in literature for an AD-cell cycle-associated
emergence from a quiescent state and researchers have
looked at it as a recapitulation or vestige of an evolutionarily
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Table 1

Marker

Role

Association with Alzheimer disease

Cyclin A
Cyclin B
Cyclin C
Cyclin D (D1, D3)
Cyclin E
p34cdc2/cdk 1
Cdk4/Cdk6
Cdk5/p25/p35
Nclk cdc2-like kinase
Cdk7/MPM2
Cdc42/rac
p21ras
MRG 15
Ki-67
p105/pRb
PCNA
p107/pRb
c-myc
p53/MDM2
ATM
Raf/Raf-1
p16INK4a p18p15p19
p27/Kip1
WAF-1/p21/Cip1
Plk1/cdc5
Polo-like kinase
PP2A or PP2B
PP-1
Cdc25 Cdc25A
PKC/Wnt path
PKA
PKN
PI3K
AKT/PKB/RAC
TGFBeta/TAK
p44/p42 MAPK (ERK1/2)
CamK
p38 MAPK
JNK/(SAPK-2/3)-alpha gamma
MEK
GSK-3 and
beta Catenin
P120/E-cadherin
c-fos
14-3-3/14-3-3zeta
c-jun/p38, AP-1
Fyn
p53

S to G2/M
G2/M
No known role
G0/G1/lateG1/S
G1 to G1/S
Late G2/M
G1/G1/S
G2 D1, D3 G1 Cyclins
Cyclin A kinase
CDK activated kinase
GTPase/cell division
G protein/MAPK
M phase regulator
LateG1,S,G2,M
G2/M TF
non cell-cycle specific
Cdk2/4/6, check pt
S to G2 checkpoint
Repressor complex
Check-point
Check point kinase
CyclinD/cdk4/6 inhibitors of M phase
Cyclin D and E/cdk7 inhibitor
Multi-Cyclin/cdk-inhibitor (G1 and S)

[95, 96]
[97–99]

[118, 119]
[120]
[97, 120]
[105, 120]
[99]
[77, 105] (negative association)
[77] (negative association)
[118, 120, 121]
[77]
[117]
[101, 122]
[77] (negative association), [101]
[118]

G2/M M check point

[123]

Phosphatase (Cdk5, cdc2)
Phosphatase G2/M
Translation control
Kinase
Kinase
Kinase
Kinase
Kinase
MAP kinase
Kinase Ca/calmodulin regulated
Kinase
Kinase (stress activated)
MAPK kinase

[124–126]
[112, 124]
[127, 128]
[129–132]
[133, 134]
[135]
[136, 137]
[135, 138, 139]
[140, 141]
[95, 142–146]
[147]
[146, 148, 149]
[146, 150]
[122, 151]

Proline-dependent protein kinase (PDPK)

[111, 112, 131, 138, 152–157]

Adhesion complex
TF/regulator
Adaptor protein
TF component
Transcription factor
TF/DNA damage

[158]
[159]
[160, 161]
[159, 162, 163]
[164, 165]
[97, 166]

[98–101]
[97, 102]
[95, 96, 103, 104]
[105–108]
[109–114]
[109, 115, 116]
[101, 117]
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Table 1: Continued.

Marker

Role

Association with Alzheimer disease

Rho
Rap Rab
Sos-1
Grb-2

G-protein
G-protein
Guanine nucleotide exchange factor
Adaptor

[135]
[117]
[167]
[167]

Modified and reprinted with permission of CNS Neurol Disord Drug Targets [92].

conserved process [82, 83] (Table 1). Recently reversion in
AD pathology has been demonstrated by anticancer drugs
[84]. Furthermore, AD-associated proteins and the cell cycle
activation from mitotic drive are intimately linked to tau proteins as well as to A𝛽, the extracellular lesion associated with
the disease [85–90]. NO has both genotoxic and angiogenic
properties and has been reported to inhibit the release of
mitogen from platelets. Another strategy for tumor treatment
has focused on the inhibition of tumor angiogenesis. It has
been well established that angiogenesis is a critical event in
tumor growth and metastasis [91]. Increased NO production
may selectively support mutant p53 cells and may also
contribute to tumor angiogenesis by upregulation of vascular
endothelial growth factor [92]. There is a growing scientific
agreement that antioxidants, particularly the polyphenolic forms, may help lower the incidence of disease, such
as certain cancers, cardiovascular, and neurodegenerative
diseases, DNA damage, or even have antiaging properties.
On the other hand, questions remain as to whether some
antioxidants or phytochemicals potentially could do more
harm than good, as an increase in glycation-mediated protein
damage (carbonyl stress) and some risk has been reported. A
recent review highlights both anti- and prooxidant properties
associated with polyphenolic compounds [93]. Nevertheless,
the quest for healthy aging has led to the use of antioxidants as a means to disrupt age-associated deterioration in
physiological function, dysregulated metabolic processes, or
prevention of many age-related diseases. Although a diet rich
in polyphenolic forms of antioxidants does seem to offer hope
in delaying the onset of age-related disorders, it is still too
early to define their exact clinical benefit for treating agerelated diseases. Regardless of where the debate will end, it is
clear that any deficiency in antioxidant vitamins or adequate
enzymatic antioxidant defenses can shift the redox balance in
some diseases [94].

8. Conclusion and Future Remarks
The absence of neuronal control (e.g., perivascular nerves)
in tumor vessels suggests that endothelial-derived vasoactive substance, namely NO and ET-1, may be key factors
in controlling tumor blood flow during tumor growth
and metastasis. An imbalance between endothelial-derived
vasoconstrictors and vasodilators, along with deficiency of
antioxidant systems may result in mitochondria lesions in
tumors. NO-induced mitochondrial failure is a causative
factor in the pathogenesis of tumors, especially tumor angiogenesis. Conversely, recent studies have shown that apart

from vasodilator and antiplatelet activities, there are other
actions of NO that might be regarded as “antiatherogenic”
(probably also “antiangiogenic”). NO has both genotoxic and
angiogenic properties and has been reported to inhibit the
release of mitogen from platelets. Another strategy for tumor
treatment has focused on the inhibition of tumor angiogenesis. Increased NO production may also contribute to tumor
angiogenesis by upregulation of vascular endothelial growth
factor. We hypothesize that mitochondrial involvement in
this cascade may be a major factor that controls tumor growth
and metastasis. Future studies of mitochondrial pathophysiology in various benign and malignant tumors, including
colorectal, liver, and brain cancer may provide new insights in
carcinogenesis and may lead to rational targets and strategies
for better and more effective cancer treatments.
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